(Q38097385)

28 August 2017

title

Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities (English)

1 reference

28 August 2017

1 reference

1

Rhoanne C McPherson

1 reference

28 August 2017

Stephen M Anderton

2

1 reference

28 August 2017

publication date

9 April 2013

1 reference

Journal of Neuroimmune Pharmacology

28 August 2017

published in

1 reference

28 August 2017

volume

8

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

774-790

1 reference

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

What is the blood-brain barrier (not)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Complementary contribution of CD4 and CD8 T lymphocytes to T-cell infiltration of the intact and the degenerative spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

How type I interferons shape myeloid cell function in CNS autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Isolation of myelin basic protein-reactive T-cell lines from normal human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Role of genetic background in P selectin-dependent immune surveillance of the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Corticosteroids for the long-term treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Evidence for use of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Taming of macrophage and microglial cell activation by microRNA-124.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Central memory CD4+ T cells dominate the normal cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Effect of anti-interferon-gamma and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

B cells regulate autoimmunity by provision of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Not always the bad guys: B cells as regulators of autoimmune pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Identification of autoantibodies associated with myelin damage in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Autoimmune T cell responses in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Increased proportion of CD4+CDw29+CD45R-UCHL-1+ lymphocytes in the cerebrospinal fluid of both multiple sclerosis patients and healthy individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Fate mapping of IL-17-producing T cells in inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Immunological tolerance using synthetic peptides--basic mechanisms and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Activation of CD4⁺ Foxp3⁺ regulatory T cells proceeds normally in the absence of B cells during EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Early predictors of non-response to interferon in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Natalizumab: A new treatment for relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Role of CD8+ T cells in murine experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Multiplicity of cerebrospinal fluid functions: New challenges in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Interferon-gamma confers resistance to experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

De novo production of antigen-specific suppressor cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

EAE mediated by a non-IFN-γ/non-IL-17 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Genetic proof for the transient nature of the Th17 phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

TLR-activated B cells suppress T cell-mediated autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Peptide-based therapeutic vaccines for allergic and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Recognition of a high affinity MHC class I-restricted epitope of myelin oligodendrocyte glycoprotein by CD8⁺ T cells derived from autoantigen-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Cutting edge: IL-6-dependent autoimmune disease: dendritic cells as a sufficient, but transient, source

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Sudden unexpected death on fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Interferon-beta: mechanism of action and dosing issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Primary progressive multiple sclerosis takes centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Prevention of arthritis by interleukin 10-producing B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Lack of evidence for use of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Therapy with glatiramer acetate for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Antigen-induced IL-10+ regulatory T cells are independent of CD25+ regulatory cells for their growth, differentiation, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Foxp3⁺ Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Microglial cell activation and proliferation precedes the onset of CNS autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Immune cell entry to central nervous system--current understanding and prospective therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Recent developments in multiple sclerosis therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Active induction of experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Prevalence Rate and Age of Acquisition of Antibodies against JC Virus and BK Virus in Human Sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Multiple sclerosis: an immune or neurodegenerative disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Axonal pathology in multiple sclerosis: relationship to neurologic disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Disturbed regulatory T cell homeostasis in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Tight junctions of the blood-brain barrier: development, composition and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Therapeutic peptide vaccines for treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Molecular antagonism and plasticity of regulatory and inflammatory T cell programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

T-bet is essential for encephalitogenicity of both Th1 and Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9453-9

B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization

21 January 2018

1 reference

12 December 2020

Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo

1 reference

12 December 2020

T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis

1 reference

12 December 2020

Treatment of established chronic relapsing experimental allergic encephalomyelitis with anti-L3T4 antibodies

1 reference

12 December 2020

Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10

1 reference

12 December 2020

High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations

1 reference

12 December 2020

T-lymphocyte entry into the central nervous system

1 reference

12 December 2020

Attachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis

1 reference

12 December 2020

Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein

1 reference

12 December 2020

B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide

1 reference

12 December 2020

The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells

1 reference

12 December 2020

Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion

1 reference

12 December 2020

Amelioration of Autoimmune Encephalomyelitis by Myelin Basic Protein Synthetic Peptide-Induced Anergy

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats

1 reference

12 December 2020

ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro

1 reference

12 December 2020

Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline

1 reference

12 December 2020

Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group

1 reference

12 December 2020

Oligodendrocyte lysis by CD4+ T cells independent of tumor necrosis factor

1 reference

12 December 2020

Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker

1 reference

12 December 2020

Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level

1 reference

12 December 2020

CD4+CD25+ Regulatory T Cells Cure Murine Colitis: The Role of IL-10, TGF-β, and CTLA4

1 reference

12 December 2020

Inhibition of the induction of alloreactivity with mitoxantrone

1 reference

12 December 2020

Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins

1 reference

12 December 2020

Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE).

1 reference

12 December 2020

Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation

1 reference

12 December 2020

Multiple Sclerosis: Distribution of T Cell Subsets Within Active Chronic Lesions

1 reference

12 December 2020

Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin

1 reference

12 December 2020

IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice

1 reference

12 December 2020

Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma

1 reference

12 December 2020

IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide

1 reference

12 December 2020

Encephalitogenic activity of truncated myelin oligodendrocyte glycoprotein (MOG) peptides and their recognition by CD8+ MOG-specific T cells on oligomeric MHC class I molecules

1 reference

12 December 2020

Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice

1 reference

12 December 2020

Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.

1 reference

12 December 2020

Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors

1 reference

12 December 2020

Myelin-reactive, TGF-β-induced regulatory T cells can be programmed to develop Th1-like effector function but remain less proinflammatory than myelin-reactive Th1 effectors and can suppress pathogenic T cell clonal expansion in vivo

1 reference

12 December 2020

Identification of T cell subsets and B lymphocytes in mouse brain experimental allergic encephalitis lesions.

1 reference

12 December 2020

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

1 reference

12 December 2020

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

1 reference

12 December 2020

Mapping of a susceptibility gene for multiple sclerosis to the 51 kb interval between G511525 and D6S1666 using a new method of haplotype sharing analysis

1 reference

12 December 2020

T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis

1 reference

12 December 2020

Oligodendrocyte-macrophage interactions in vitro triggered by specific antibodies

1 reference

12 December 2020

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 reference

12 December 2020

Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple sclerosis.

1 reference

12 December 2020

High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay

1 reference

12 December 2020

Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network

1 reference

12 December 2020

Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice--implications for autoimmunity

1 reference

12 December 2020

Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles

1 reference

12 December 2020

Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo

1 reference

12 December 2020

Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression

1 reference

12 December 2020

Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells

1 reference

12 December 2020

The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis

1 reference

12 December 2020

Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta

1 reference

12 December 2020

IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells.

1 reference

12 December 2020

Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein

1 reference

12 December 2020

GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Multiple sclerosis☆Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages

1 reference

12 December 2020

10.1007/S11481-013-9453-9

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1036231728

0 references

1 reference